News - Alkermes


Current filters:


Popular Filters

FDA approves Bydureon Pen for type 2 diabetes

FDA approves Bydureon Pen for type 2 diabetes


Anglo-Swedish drug major AstraZeneca says the US Food and Drug Administration has approved the Bydureon…

AlkermesAmylinAstraZenecaBristol-Myers SquibbBydureonDiabetesPharmaceuticalRegulationUSA

Alkermes reveals candidates for MS, cancer and pain


US drugmaker Alkermes (Nasdaq: ALKS) has unveiled three new drug candidates for the treatment of multiple…

AlkermesBiogen IdecNeurologicalNorth AmericaOncologyPharmaceuticalResearchTecfidera

Alkermes boosted by positive Ph II data on ALKS 5461 for major depressive disorder


Ireland-headquartered Alkermes (Nasdaq: ALKS) saw its shares rise 16% to $29.72, after it announced positive…


FDA approves Otsuka and Lundbeck's once-monthly Abilify Maintena for schizophrenia


Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) and Danish partner Lundbeck (LUND: DC) have received…

Abilify MaintenaAlkermesLundbeckNeurologicalNorth AmericaOtsukaPharmaceuticalRegulation

Alkermes and J&J initiate Ph III trial of three-month Invega Sustenna


USA-based Alkermes (Nasdaq: ALKS) and partner health care giant Johnson & Johnson (NYSE: JNJ) have started…

AlkermesInvega SustennaJohnson & JohnsonNeurologicalPharmaceuticalResearch

Elan cashes in 76% chunk of its Alkermes stake for $381 million; Roche updates on Illumina bid


Ireland-based Elan Corp (NYSE: ELN) revealed yesterday that it has raised around $381 million in net…

AlkermesElanElan Drug TechnologiesFinancialIlluminaMergers & AcquisitionsPharmaceuticalRoche

Alkermes pulls MAA for Megestrol product


The European Medicines Agency says it has been formally notified by the Irish subsidiary of US drugmaker…


2011 financial briefs for Alkermes, Allergan, Gilead and Vertex


Among the plethora of financial results being reported by US biotech and pharmaceutical companies were…

AlkermesAllerganBiotechnologyFinancialGilead SciencesPharmaceuticalVertex

FDA finally approves Bydureon


There was good news on Friday for USA-based Amylin Pharmaceuticals (Nasdaq: AMLN) and Alkermes (Nasdaq:…

AlkermesAmylinBydureonDiabetesEli LillyNorth AmericaPharmaceuticalRegulation

Strong results for Alkermes’ ALKS 5461 in major depressive disorder


US drugmaker Alkermes (Nasdaq: ALKS) yesterday released positive early clinical results for a central…


Alkermes completes Elan DT buy; signs manufacturing deal


US drugmaker Alkermes (Nasdaq: ALKS) says it has now completed its previously-announced acquisition of…

AlkermesElanElan Drug TechnologiesMergers & AcquisitionsPharmaceutical

Strong new data on Novo Nordisk’s Victoza and Lilly/Amylin’s Bydureon presented at EADS


A significantly higher proportion of patients reached the target for blood sugar control (HbA1c target…

AlkermesAmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

Alkermes shareholders vote in favor of merger with Elan Drug Technology


Shareholders of USA-based Alkermes (Nasdaq; ALKS) have voted to approve the previously-announced $960…

AlkermesElanElan Drug TechnologiesMergers & AcquisitionsPharmaceutical

US FDA sets PDUFA action dates for Bydureon and peginesatide


US drugmakers Amylin Pharmaceuticals (Nasdaq: AMLN), Eli Lilly (NYSE: LLY) and Alkermes (Nasdaq: ALKS)…

AffymaxAlkermesAmylinBydureonDiabetesEli LillyNorth AmericaOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Amylin and Eli Lilly submit CRL reply on Bydureon to US FDA


US biotech Amylin Pharmaceuticals (Nasdaq: AMLN), drug major Eli Lilly (NYSE: LLY) and partner Alkermes…

AlkermesAmylinBiotechnologyBydureonDiabetesEli LillyNorth AmericaPharmaceuticalRegulation

Back to top